Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

7(70.0%)

Phase 1

2(20.0%)

Phase 3

1(10.0%)

10Total

Phase 2(7)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT00908687Phase 2Completed

A/H5N1/LT Dose Ranging Study

Role: lead

NCT00565461Phase 2Completed

LT Vaccine Patch Self-Administration Study

Role: lead

NCT01067781Phase 2Completed

Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch

Role: lead

NCT00751777Phase 2Completed

Traveler's Diarrhea (TD) Automated Process

Role: lead

NCT01353534Phase 1Completed

Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine

Role: lead

NCT00516659Phase 2Completed

ETEC Logistics Trial (TREK)

Role: lead

NCT01040325Phase 2Completed

Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study

Role: lead

NCT00672035Phase 2Completed

Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study

Role: lead

NCT00993681Phase 3Completed

Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study

Role: lead

NCT00532792Phase 1Completed

A/H5N1 Dose Ranging Study With Adjuvant Patch

Role: lead

All 10 trials loaded